ACTRN12612000281897
Recruiting
未知
In post menopausal women, does administration of Estradot 50mcg patches twice weekly and/or Andro-Feme cream, 1/2ml daily, for eight weeks, compared to placebo improve dry eye clinical indices and biomarkers
School of Optometry and Vision Science0 sites80 target enrollmentMarch 9, 2012
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Dry Eye
- Sponsor
- School of Optometry and Vision Science
- Enrollment
- 80
- Status
- Recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Post menopausal women who has permanent cessation of menses for at least one year with dry eye
Exclusion Criteria
- •Experience normal menstrual cycle
- •History of corneal or refractive surgery
- •Diagnosis of Sjogren’s Syndrome
- •History of hormone therapy within the past 12 months
- •Prior diagnosis of infectious disease transmittable by blood (eg HIV/AIDS, Hepatitis)
- •Eye surgery within 6 months immediately prior to enrolment for this study
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
eoadjuvant therapy for postmenopausal women with ER and/or PgR positive breast cancer. A randomized open phase II trial evaluating the efficacy of a 6 months preoperative treatment withLetrozole (2.5 mg/day) with or withoutZoledronic acid (4 mg every 4 weeks). - FEMZONEEUCTR2004-004007-37-DEovartis Pharma GmbH
Active, not recruiting
Phase 1
ocal Oestrogen Treatment in Postmenopausal Women Undergoing Pelvic Organ Prolapse Surgery (LOTUS)EUCTR2014-000179-18-GBniversity of Birmingham100
Recruiting
Not Applicable
A randomised cross-over trial to examine the effects of calcium citrate on blood calcium levels, blood coagulation and blood pressure in normal postmenopausal womeCardiovascular diseaseDiet and Nutrition - Other diet and nutrition disordersCardiovascular - HypertensionCardiovascular - Diseases of the vasculature and circulation including the lymphatic systemACTRN12614000865617niversity of Auckland40
Completed
Phase 3
IBCSG IX - Adjuvant therapy in postmenopausal patients with node negative breast cancerBreast CancerCancer - BreastACTRN12607000029493International Breast Cancer Study Group900
Active, not recruiting
Not Applicable
eoadjuvant hormone therapy for postmenopausal women with ER and/or PgR positive primary breast cancer: A multi-center study to determine the optimum length of treatment with Femara (letrozole 2.5mg daily) on tumour regression to permit breast conserving surgery.Postmenopausal women with ER and/or PgR positive primary breast cancerEUCTR2005-000661-19-GBovartis Pharmaceuticals UK Ltd